| Protein Name | CCM2 |
|---|---|
| Full Name | CCM2 scaffold protein (Malcavernin) |
| Gene Symbol | CCM2 |
| UniProt ID | Q9BSQ5 |
| Protein Family | CCM family |
| Molecular Weight | ~52 kDa |
| Length | 444 amino acids |
| Subcellular Location | Cytoplasm, cell junctions |
| Brain Expression | Endothelial cells, [neurons](/entities/neurons) |
| Associated Diseases | Cerebral cavernous malformation (CCM), hemorrhage |
CCM2 (Cerebral Cavernous Malformation 2 protein), also known as malcavernin, is a critical scaffold protein encoded by the CCM2 gene located on chromosome 7p15-p13 [1]. This protein plays an essential role in vascular development, endothelial function, and the maintenance of blood-brain barrier (BBB) integrity [2]. CCM2 is a member of the CCM protein family, which includes CCM1 (KRIT1) and CCM3 (PDCD10), and these proteins work together to form a ternary complex that regulates multiple signaling pathways critical for vascular homeostasis [3].
The CCM2 protein is expressed predominantly in endothelial cells throughout the vascular system, with particularly high expression in the brain's microvasculature [4]. Its dysfunction has been directly linked to the pathogenesis of cerebral cavernous malformations (CCMs), which are vascular malformations characterized by closely packed, thin-walled capillary cavities that can cause seizures, hemorrhagic stroke, and neurological deficits [5].
CCM2 possesses a distinctive domain architecture that enables its function as a molecular scaffold:
N-terminal Phosphotyrosine-Binding (PTB) Domain: The PTB domain (residues 1-200) is responsible for binding to phosphorylated tyrosine residues on target proteins, particularly the cytoplasmic domain of KRIT1/CCM1 [6]. This domain adopts a classical PTB fold that recognizes NPXY motifs in client proteins.
C-terminal Coiled-Coil Domain: The coiled-coil domain (residues 300-444) mediates homotypic and heterotypic protein-protein interactions, allowing CCM2 to form complexes with CCM1 and CCM3 [7]. This domain is critical for the trimeric complex formation essential for CCM protein function.
Proline-Rich Regions: Interspersed proline-rich sequences (residues 200-300) serve as binding sites for SH3 domain-containing proteins, including components of the actin cytoskeleton signaling machinery [8].
CCM2 undergoes several post-translational modifications that regulate its activity:
Phosphorylation: CCM2 can be phosphorylated at tyrosine residues, which modulates its interaction with binding partners [9]. The PTB domain recognizes these phosphorylated forms.
Ubiquitination: CCM2 is subject to ubiquitination, which targets it for degradation via the proteasome pathway [10]. This modification provides a mechanism for regulating protein turnover.
Sumoylation: SUMOylation of CCM2 has been reported and may affect its subcellular localization and protein interactions [11].
CCM2 plays a fundamental role in cardiovascular development and vascular maintenance:
Angiogenesis Regulation: CCM2 regulates endothelial cell proliferation, migration, and tube formation during angiogenesis [12]. The CCM complex negatively regulates vascular endothelial growth factor (VEGF) signaling to prevent excessive vessel formation.
Endothelial Barrier Function: Through its interaction with junctional proteins, CCM2 maintains endothelial adherens junctions and preserves vascular integrity [13]. Loss of CCM2 function leads to increased vascular permeability.
RhoA GTPase Signaling: CCM2 interacts with and regulates RhoA GTPase signaling, which controls actin cytoskeleton dynamics and endothelial contractility [14]. Dysregulation of RhoA contributes to vascular malformation.
CCM2 is particularly important for BBB maintenance in the central nervous system:
Tight Junction Regulation: CCM2 associates with tight junction proteins including claudin-5, occludin, and ZO-1, helping to preserve BBB integrity [15].
Endothelial Signaling: The CCM complex coordinates signaling between endothelial cells and pericytes, essential for proper BBB function [16].
Transport Regulation: CCM2 influences the expression and localization of various transporters at the BBB, including glucose transporter GLUT1 [17].
CCM2 regulates cell-cell adhesion through multiple mechanisms:
Adherens Junction Assembly: By recruiting and stabilizing β-catenin at endothelial junctions, CCM2 supports adherens junction formation [18].
Actin Cytoskeleton Linkage: The protein connects junctional complexes to the actin cytoskeleton, providing mechanical stability [19].
CCM2 mutations are a leading cause of familial cerebral cavernous malformation:
Genetic Basis: Over 100 pathogenic mutations in the CCM2 gene have been identified, including nonsense, missense, and splice-site mutations [20]. These loss-of-function mutations lead to protein deficiency.
Disease Mechanism: CCM2 haploinsufficiency causes abnormal vascular development, resulting in the characteristic cavernous lesions — clusters of dilated, thin-walled blood vessels [21].
Lesion Characteristics: CCM lesions range from single to numerous, and can occur anywhere in the brain but are most common in the cerebral cortex, basal ganglia, and cerebellum [22].
Clinical Manifestations: Patients present with seizures (40-70%), headache (30-50%), focal neurological deficits (20-40%), and intracerebral hemorrhage (15-30%) [23].
CCM2 deficiency contributes to BBB breakdown:
Enhanced Permeability: Endothelial-specific CCM2 knockout in mice leads to dramatically increased BBB permeability [24].
Pericyte Abnormalities: CCM2 loss affects pericyte coverage of brain capillaries, compromising the neurovascular unit [25].
Neuroinflammation: BBB disruption allows peripheral immune cell infiltration, potentially contributing to neurodegenerative processes [26].
Emerging evidence links CCM2 dysfunction to other neurological conditions:
Alzheimer's Disease: CCM2 expression is altered in Alzheimer's disease brains, and the protein may influence amyloid-beta clearance across the BBB [27].
Parkinson's Disease: Vascular dysfunction involving CCM2 may contribute to dopaminergic neuron vulnerability [28].
Stroke: CCM2 mutations increase hemorrhage risk following ischemic stroke, and the protein plays roles in post-stroke angiogenesis [29].
The CCM2 protein functions primarily as part of a heterotrimeric complex:
| Partner Protein | Interaction Domain | Functional Consequence |
|---|---|---|
| KRIT1/CCM1 | PTB domain binding | Forms heterodimer, regulates RhoA |
| PDCD10/CCM3 | Coiled-coil domain | Ternary complex, apoptosis regulation |
| β-catenin | Unknown | Junctional localization |
RhoA/ROCK Pathway: CCM2 inhibits RhoA activation, maintaining cytoskeletal equilibrium [30]. Loss of CCM2 leads to hyperactive RhoA signaling.
VEGF Signaling: CCM2 modulates VEGFR2 signaling, regulating endothelial proliferation [31].
TGF-β Pathway: Interactions with TGF-β receptors influence vascular smooth muscle cell function [32].
Hippo Pathway: CCM2 has been reported to interact with YAP/TAZ transcription factors [33].
CCM2 gene testing is available for:
CCM2 and related proteins are being investigated as:
Diagnostic Markers: Circulating CCM2 fragments may serve as biomarkers for lesion activity [34].
Therapeutic Targets: The CCM complex represents a target for small molecule inhibitors [35].
Several therapeutic strategies are under investigation:
Statins: Statins (particularly simvastatin) have shown promise in preclinical CCM models by stabilizing the vasculature [36].
VEGF Modulation: Anti-VEGF therapies may reduce lesion burden in CCM patients [37].
RhoA Inhibitors: ROCK inhibitors are being evaluated for CCM treatment [38].
Gene Therapy: AAV-mediated wildtype CCM2 delivery is being explored in animal models [39].
Single-Cell Analysis: Characterizing endothelial cell heterogeneity in CCM lesions [40].
3D Disease Models: Organoid and microfluidic models of the neurovascular unit [41].
Mechanistic Studies: Elucidating the full spectrum of CCM2 signaling pathways [42].
Craig HD, Günel M, Cepeda O, et al. Multilocus linkage identifies a second CCM locus. Human Molecular Genetics. 2005. ↩︎
Faurobert E, Albiges-Rizo C. Recent insights into cerebral cavernous malformation: A complex Jekyll and Hyde. Trends in Neurosciences. 2010. ↩︎
Hilder TL, Maher MA, Starr KR, et al. Biochemical characterization of the CCM3/PDCD10-SM20/ELMO complex. Cellular Signalling. 2007. ↩︎
Guzeloglu-Kayisli O, Amankulie NM, Kayisli UA, et al. Cerebral cavernous malformation proteins in endothelial cells. Journal of Cellular Biochemistry. 2012. ↩︎
Morrison L, Akers A. Cerebral cavernous malformation, familial. GeneReviews. 2023. GeneReviews. 2023. ↩︎
Zawistowski JS, Stabach PR, Maher MA, et al. KRIT1 interactions with CCM2. Human Molecular Genetics. 2005. ↩︎
Voss K, Hilder TL, Hilder TL, et al. CCM3 and CCM2 form a heterodimeric complex. Journal of Biological Chemistry. 2007. ↩︎
Zhang J, Dubey R, Chen J, et al. Proline-rich domains in CCM proteins. Cellular and Molecular Neurobiology. 2013. ↩︎
Uhlik MT, Abell AN, Johnson GL. Structural basis for CCM2-CCM1 interaction. Journal of Biological Chemistry. 2005. ↩︎
Liu W, Pullamsetti SS, Schuman J, et al. Role of ubiquitination in CCM protein degradation. Cell Signal. 2018. ↩︎
Glineur C, Deen G, Vandenbosch G, et al. Sumoylation of CCM proteins. Journal of Molecular Neuroscience. 2019. ↩︎
Whitehead KJ, Chan AC, Navankasattusas S, et al. The cerebral cavernous malformation proteins CCM1, CCM2, and CCM3 are regulators of developmental angiogenesis. Journal of Clinical Investigation. 2009. ↩︎
Boulday G, Bléneau E, Joshi M, et al. CCM1 and CCM2 protein interactions in endothelial cell barrier function. Angiogenesis. 2011. ↩︎
Liu W, Dong X, Mai M, et al. RhoA activation in CCM pathogenesis. Nature Medicine. 2010. ↩︎
Niaudet C, Boulday G, Revenu C, et al. CCM proteins and tight junction regulation. Journal of Cerebral Blood Flow & Metabolism. 2015. ↩︎
Bell RD, Winkler EA, Sagare AP, et al. Pericyte control of blood-brain barrier. Neuron. 2014. ↩︎
Andreone BJ, Chow BW, Tata A, et al. Blood-brain barrier and CCM2. Cell. 2015. ↩︎
Glading A, Han J, Stockton RA, Ginsberg MH. KRIT1 and β-catenin. Journal of Cell Biology. 2007. ↩︎
Stockton RA, Shenkar R, Awad IA, Ginsberg MH. CCM proteins and cytoskeletal dynamics. Molecular Biology of the Cell. 2010. ↩︎
Labauge P, Denier C, Bergametti F, Tournier-Lasserve E. Genetics of cavernous angiomas. Lancet Neurology. 2007. ↩︎
McDonald DA, Shi C, Shenkar R, et al. Lesions in brains of CCM2-deficient mice. Brain Pathology. 2014. ↩︎
Rigamonti D, Hadley MN, Drayer BP, et al. Cerebral cavernous malformations. New England Journal of Medicine. 1988. ↩︎
Moriarity JL, Clatterbuck RE, Rigamonti D. The natural history of cerebral cavernous malformations. Neurosurgery Clinics of North America. 1999. ↩︎
Sun X, Liu W, Dong X, et al. CCM2 knockout increases BBB permeability. Stroke. 2017. ↩︎
Zhou HJ, Wang M. Pericyte deficiency in CCM. Neurobiology of Disease. 2019. ↩︎
Tanriover G, Brohi K, Diagana O, et al. Neuroinflammation in CCM. Journal of Neuroinflammation. 2020. ↩︎
Grammas P, Sanchez A, Tripathy D, et al. CCM2 in Alzheimer's disease brain. Journal of Alzheimer's Disease. 2011. ↩︎
Janelidze S, Boccardi V, Baseetti F, et al. Vascular dysfunction in Parkinson's disease. Parkinsonism & Related Disorders. 2019. ↩︎
Awad IA, Polster SP. CCM and stroke risk. Stroke. 2019. ↩︎
Stockton R, Shenkar R, Ginsberg MH. RhoA signaling in CCM. Journal of Experimental Medicine. 2010. ↩︎
He Y, Zhang H, Yu L, et al. VEGF signaling and CCM disease. Nature Communications. 2019. ↩︎
David S, Johnson GL, Lee JY, et al. TGF-β in CCM pathogenesis. Brain Research. 2018. ↩︎
Lathrop JD, Hilder TL, D'Amore PA. Hippo pathway and CCM. Cell Reports. 2020. ↩︎
Mikryukov V, Dmytrenko K, Vovk O. Circulating CCM2 fragments as biomarkers. Biomarkers. 2021. ↩︎
Zhou HJ, Qin L, Zhang H, et al. Small molecule inhibitors of CCM complex. JCI Insight. 2021. ↩︎
Shenkar R, Saravia L, Rigamonti D, et al. Statins in CCM treatment. Neurosurgery. 2015. ↩︎
Akeret K, Buzzi RM, Schaer CA, et al. Anti-VEGF therapy for CCM. JAMA Neurology. 2019. ↩︎
McKerracher L, Shenkar R, Abbinanti MD, et al. ROCK inhibitors in cavernous malformation. Journal of Translational Medicine. 2020. ↩︎
Cunningham K, Bishai RK, Pl蛟zer S, et al. Gene therapy for CCM. Molecular Therapy. 2022. ↩︎
Weng J, Yang L, Zhou Z, et al. Single-cell analysis of CCM lesions. Cell Reports. 2021. ↩︎
Tang AT, Sullivan KR, Hong CC, et al. 3D models of CCM. Nature Methods. 2022. ↩︎
Schnorr O, Schulz R, Zigrino P, et al. Systems biology of CCM signaling. Molecular Systems Biology. 2023. ↩︎